12:00 AM
Dec 24, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Ilaris canakinumab regulatory update

EMA's CHMP issued a positive opinion recommending to expand the indication of Ilaris canakinumab from Novartis to include treatment of cryopyrin-associated periodic syndromes (CAPS) in patients ages...

Read the full 111 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >